Tiffany Goh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tiffany Goh has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anna Waterhouse
The University of Sydney Nano Institute
4 shared publications - Jasneil Singh
School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia
3 shared publications - Lingzi Gao
School of Medical Sciences Faculty of Medicine and Health The University of Sydney Camperdown NSW 2006 Australia
3 shared publications - Jun Ki Hong
School of Chemistry The University of Sydney Sydney NSW 2006 Australia
2 shared publications - Lining Arnold Ju
The University of Sydney
2 shared publications - Alexander M. Ruhoff
Heart Research Institute, The University of Sydney, Newtown, NSW 2042, Australia
1 shared publication
Latest Publications
- Open Access
- 28 October 2026
- Published by Elsevier in Biomaterials
- Vol. 339
Biomaterial thrombosis-on-a-chip: Real-time visualisation of biomaterial thrombosis at clinical heparin levels
- 28 October 2026
- Published by Elsevier in Biomaterials
- Vol. 339
Open AccessBiomaterial thrombosis-on-a-chip: Real-time visualisation of biomaterial thrombosis at clinical heparin levels
- Open Access
- 17 May 2024
- Published by Wiley in Advanced Science
- Vol. 11 (30) , e2401524
Platelet Adhesion and Activation in an ECMO Thrombosis‐on‐a‐Chip Model
Use of extracorporeal membrane oxygenation (ECMO) for cardiorespiratory failure remains complicated by blood clot formation (thrombosis), triggered by biomaterial surfaces and flow conditions. Thrombosis may result in ECMO circuit changes, cause red blood cell hemolysis, and thromboembolic events. Medical device thrombosis is potentiated by the interplay between biomaterial properties, hemodynamic flow conditions and patient pathology, however, the contribution and importance of these factors are poorly understood because many in vitro models lack the capability to customize material and flow conditions to investigate thrombosis under clinically relevant medical device conditions. Therefore, an ECMO thrombosis‐on‐a‐chip model is developed that enables highly customizable biomaterial and flow combinations to evaluate ECMO thrombosis in real‐time with low blood volume. It is observed that low flow rates, decelerating conditions, and flow stasis significantly increased platelet adhesion, correlating with clinical thrombus formation. For the first time, it is found that tubing material, polyvinyl chloride, caused increased platelet P‐selectin activation compared to connector material, polycarbonate. This ECMO thrombosis‐on‐a‐chip model can be used to guide ECMO operation, inform medical device design, investigate embolism, occlusion and platelet activation mechanisms, and develop anti‐thrombotic biomaterials to ultimately reduce medical device thrombosis, anti‐thrombotic drug use and therefore bleeding complications, leading to safer blood‐contacting medical devices.
- 17 May 2024
- Published by Wiley in Advanced Science
- Vol. 11 (30) , e2401524
Open AccessPlatelet Adhesion and Activation in an ECMO Thrombosis‐on‐a‐Chip Model
Use of extracorporeal membrane oxygenation (ECMO) for cardiorespiratory failure remains complicated by blood clot formation (thrombosis), triggered by biomaterial surfaces and flow conditions. Thrombosis may result in ECMO circuit changes, cause red blood cell hemolysis, and thromboembolic events. Medical device thrombosis is potentiated by the interplay between biomaterial properties, hemodynamic flow conditions and patient pathology, however, the contribution and importance of these factors are poorly understood because many in vitro models lack the capability to customize material and flow conditions to investigate thrombosis under clinically relevant medical device conditions. Therefore, an ECMO thrombosis‐on‐a‐chip model is developed that enables highly customizable biomaterial and flow combinations to evaluate ECMO thrombosis in real‐time with low blood volume. It is observed that low flow rates, decelerating conditions, and flow stasis significantly increased platelet adhesion, correlating with clinical thrombus formation. For the first time, it is found that tubing material, polyvinyl chloride, caused increased platelet P‐selectin activation compared to connector material, polycarbonate. This ECMO thrombosis‐on‐a‐chip model can be used to guide ECMO operation, inform medical device design, investigate embolism, occlusion and platelet activation mechanisms, and develop anti‐thrombotic biomaterials to ultimately reduce medical device thrombosis, anti‐thrombotic drug use and therefore bleeding complications, leading to safer blood‐contacting medical devices.
- Open Access
- 3 March 2024
- Published by Wiley in Advanced Materials Technologies
- Vol. 9 (8)
Spatiotemporally Mapped Endothelial Dysfunction at Bifurcations in a Coronary Artery‐on‐a‐Chip
Atherosclerotic plaques are commonly observed at low shear regions, in particular, the left main coronary artery (LMCA) bifurcation. Low shear regions at bifurcations promote endothelial dysfunction, a key factor initiating atherogenesis, however, mechanisms underlying this process are poorly understood. Dynamic in vitro models are critical to investigate endothelial dysfunction, but current static and vessels‐on‐chip systems typically lack physiologically complex geometries and local shear changes. Here, a bifurcating coronary artery‐on‐a‐chip is developed, mimicking the human LMCA, displaying reduced shear near the bifurcation, verified using computational fluid dynamics simulations. Over 7 days of dynamic culture, human coronary artery endothelial cells aligned with the flow and expressed more Endothelial nitric oxide synthase (eNOS) and intercellular cell adheison molecule‐1 (ICAM‐1) at high shear regions (12.7 dyn cm−2) adjacent to, but not at the bifurcation (0–3 dyn cm−2). After tumor necrosis factor‐alpha (TNFα) stimulation to induce endothelial dysfunction, spatially mapping cellular changes and shear gradients revealed cell alignment is disrupted over a larger area surrounding the bifurcation at a higher shear, and ICAM‐1 expression is increased closer to the bifurcation at a lower shear. This coronary artery‐on‐a‐chip establishes a system to spatially map endothelial cell behavior in response to differential shear and vessel geometry, enabling future studies into plaque initiation events, treatment targets, and drug screening.
- 3 March 2024
- Published by Wiley in Advanced Materials Technologies
- Vol. 9 (8)
Open AccessSpatiotemporally Mapped Endothelial Dysfunction at Bifurcations in a Coronary Artery‐on‐a‐Chip
Atherosclerotic plaques are commonly observed at low shear regions, in particular, the left main coronary artery (LMCA) bifurcation. Low shear regions at bifurcations promote endothelial dysfunction, a key factor initiating atherogenesis, however, mechanisms underlying this process are poorly understood. Dynamic in vitro models are critical to investigate endothelial dysfunction, but current static and vessels‐on‐chip systems typically lack physiologically complex geometries and local shear changes. Here, a bifurcating coronary artery‐on‐a‐chip is developed, mimicking the human LMCA, displaying reduced shear near the bifurcation, verified using computational fluid dynamics simulations. Over 7 days of dynamic culture, human coronary artery endothelial cells aligned with the flow and expressed more Endothelial nitric oxide synthase (eNOS) and intercellular cell adheison molecule‐1 (ICAM‐1) at high shear regions (12.7 dyn cm−2) adjacent to, but not at the bifurcation (0–3 dyn cm−2). After tumor necrosis factor‐alpha (TNFα) stimulation to induce endothelial dysfunction, spatially mapping cellular changes and shear gradients revealed cell alignment is disrupted over a larger area surrounding the bifurcation at a higher shear, and ICAM‐1 expression is increased closer to the bifurcation at a lower shear. This coronary artery‐on‐a‐chip establishes a system to spatially map endothelial cell behavior in response to differential shear and vessel geometry, enabling future studies into plaque initiation events, treatment targets, and drug screening.
- 12 October 2020
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 8 (21) , 5824-5845
Evaluating medical device and material thrombosis under flow: current and emerging technologies
Although blood-contacting medical devices are used widely, blood clot formation (thrombosis) leads to device failure and potentially catastrophic adverse thrombotic events for patients, such as stroke or pulomonary embolism. Systemic anti-thrombotic drugs aimed at reducing these complications do not always prevent device thrombosis and can cause increased bleeding risks. Therefore, our understanding of material thrombosis mechanisms needs to be improved in order to develop next generation blood-contacting medical devices and materials. Medical device development requires material thrombogenicity evaluation according to the International Standards 10993-4 Biological evaluation of medical devices–Selection of tests for interactions with blood, which highlights that one of the key aspects for testing is a clinically relevant flow system. In this review, we first provide an overview of the current knowledge regarding material thrombosis and important physical and biological aspects of blood flow in relation to thrombus formation. We then examine commonly used in vitro flow systems to evaluate material and medical device thrombosis, focusing on their capabilities, advantages and disadvantages. Finally, we explore recent advances in technology that will aid in improving the design and fabrication of flow systems, mechanistic analysis and computational modelling.
- 12 October 2020
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 8 (21) , 5824-5845
Evaluating medical device and material thrombosis under flow: current and emerging technologies
Although blood-contacting medical devices are used widely, blood clot formation (thrombosis) leads to device failure and potentially catastrophic adverse thrombotic events for patients, such as stroke or pulomonary embolism. Systemic anti-thrombotic drugs aimed at reducing these complications do not always prevent device thrombosis and can cause increased bleeding risks. Therefore, our understanding of material thrombosis mechanisms needs to be improved in order to develop next generation blood-contacting medical devices and materials. Medical device development requires material thrombogenicity evaluation according to the International Standards 10993-4 Biological evaluation of medical devices–Selection of tests for interactions with blood, which highlights that one of the key aspects for testing is a clinically relevant flow system. In this review, we first provide an overview of the current knowledge regarding material thrombosis and important physical and biological aspects of blood flow in relation to thrombus formation. We then examine commonly used in vitro flow systems to evaluate material and medical device thrombosis, focusing on their capabilities, advantages and disadvantages. Finally, we explore recent advances in technology that will aid in improving the design and fabrication of flow systems, mechanistic analysis and computational modelling.